Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BMS 986260 is an inhibitor of activin receptor-like kinase 5 (ALK5), also known as TGF-β receptor type I (TGF-βRI; IC50 = 0.0015 µM).1 It is selective for ALK5 over TGF-βRII (IC50 = >15 µM) and a panel of 213 additional kinases at 1 µM. BMS 986260 inhibits TGF-β-induced increases in the nuclear translocation of phosphorylated SMAD2/3 in Mv 1 Lu mink lung epithelial cells (IC50 = 0.35 µM). It decreases tumor growth in an MC-38 murine colon carcinoma model of tumor rechallenge when administered at a dose of 3.75 mg/kg per day in combination with an antibody against programmed cell death protein 1 (PD-1). BMS 986260 (10 mg/kg per day) induces hyperproliferation of chondrocytes in the femoral epiphysis, thickening of the cardiac atrioventricular valve, and inflammation in the aortic vasculature in rats.2
WARNING This product is not for human or veterinary use.
1. Discovery of BMS-
2. Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-